Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors

Emerging Therapies, Web Exclusives

Coming soon…
ASCO, Web Exclusives - July 28, 2020

A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies

Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-centered outcomes by integrating quality of life (QOL) and [ Read More ]

Uncategorized - January 5, 2016

Alectinib: an Anaplastic Lymphoma Kinase (ALK) Inhibitor

ALK Rearrangements in Lung AdenocarcinomaALK has been found to fuse with other partners, leading to potent malignant transformation.1,2 The most common among ALK fusion genes in lung cancer, specifically non–small cell lung cancer (NSCLC), is the EML4 ALK translocation fusion gene (EML4-ALK).1,3-5 The relative prevalence of ALK translocation mutations among [ Read More ]